JPS5857321A - 抗癌剤 - Google Patents
抗癌剤Info
- Publication number
- JPS5857321A JPS5857321A JP15641481A JP15641481A JPS5857321A JP S5857321 A JPS5857321 A JP S5857321A JP 15641481 A JP15641481 A JP 15641481A JP 15641481 A JP15641481 A JP 15641481A JP S5857321 A JPS5857321 A JP S5857321A
- Authority
- JP
- Japan
- Prior art keywords
- cancer cells
- gra
- lectin
- cells
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 45
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 108090001090 Lectins Proteins 0.000 claims abstract description 20
- 102000004856 Lectins Human genes 0.000 claims abstract description 20
- 239000002523 lectin Substances 0.000 claims abstract description 20
- 239000000427 antigen Substances 0.000 claims abstract description 7
- 102000036639 antigens Human genes 0.000 claims abstract description 7
- 108091007433 antigens Proteins 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 229930182830 galactose Natural products 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 28
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- 239000000243 solution Substances 0.000 abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 108010046016 Peanut Agglutinin Proteins 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract description 2
- 230000002269 spontaneous effect Effects 0.000 abstract description 2
- 101710196768 Seed lectin Proteins 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000948258 Gila Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000046095 Psophocarpus tetragonolobus Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- -1 soufflé Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (34)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15641481A JPS5857321A (ja) | 1981-10-01 | 1981-10-01 | 抗癌剤 |
| DK292182A DK292182A (da) | 1981-10-01 | 1982-06-29 | Fremgangsmaade til fremstilling af lymfocytter, der er cytotoksiske overfor cancerceller, samt glyco-associeret antigen til anvendelse derved |
| FI822325A FI77157C (fi) | 1981-10-01 | 1982-06-29 | Foerfarande foer framstaellning av glykobunden antigen och foerfarande foer framstaellning av foer kancerceller toxiska lymfocyter, som aer specifika mot denna antigen. |
| PT75148A PT75148B (en) | 1981-10-01 | 1982-06-29 | Production process of the lymphocytes fighting against cancero us cells and anti-cancer agents containing them |
| NZ201112A NZ201112A (en) | 1981-10-01 | 1982-06-29 | Preparation of a cancer-specific antigen and composition |
| HU210282A HU190803B (en) | 1981-10-01 | 1982-06-29 | Lymphocytes against carcinoma cells, process for producing them, and citostatic active agents containing the said lymphocytes |
| NO822215A NO161601C (no) | 1981-10-01 | 1982-06-29 | Fremgangsmaate for fremstilling av et glykorelatert antigen |
| AR289864A AR230731A1 (es) | 1981-10-01 | 1982-06-30 | Procedimiento para preparar un antigeno glicorrelacionado y un procedimiento para producir linfocitos citotoxicos para celulas cancerosas a partir de dicho antigeno glicorrelacionado |
| CA000406449A CA1201988A (en) | 1981-10-01 | 1982-06-30 | Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes |
| BE0/208493A BE893704A (fr) | 1981-10-01 | 1982-06-30 | Lymphocytes luttant contre les cellules cancereuses, procede pour leur production et agents anticancereux contenant ces lymphocytes ou un antigene glyco-apparente |
| SE8204058A SE8204058L (sv) | 1981-10-01 | 1982-06-30 | Cancercellangripande lymfocyter, forfarande for framstellning derav och anticancermedel innehallande nemnda lymfocyter |
| MX8210163U MX7437E (es) | 1981-10-01 | 1982-06-30 | Procedimiento para producir un antigeno glico-relacionado |
| CH551284A CH655661B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-10-01 | 1982-06-30 | |
| PH27516A PH22474A (en) | 1981-10-01 | 1982-06-30 | Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes |
| ES514450A ES8402615A1 (es) | 1981-10-01 | 1982-06-30 | Procedimiento para producir linfocitos citotoxicos de celulas de cancer utilizables en el tratamiento de este. |
| AU85458/82A AU554858B2 (en) | 1981-10-01 | 1982-06-30 | Glyco-related antigen from cancer cells |
| DD82261475A DD221917A5 (de) | 1981-10-01 | 1982-06-30 | Verfahren zur herstellung von krebszellen-cytotoxischen lymphocyten |
| DD82241290A DD209577A5 (de) | 1981-10-01 | 1982-06-30 | Verfahren zur herstellung eines glykoverwandten antigens |
| IT48724/82A IT1189305B (it) | 1981-10-01 | 1982-06-30 | Linfociti che combattono cellule di cancro,procedimento per produrli ed agenti anticancerosi che li contengono |
| CH398882A CH655660B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-10-01 | 1982-06-30 | |
| NL8202638A NL8202638A (nl) | 1981-10-01 | 1982-06-30 | Kankercellenbestrijdende lymfocyten, werkwijze voor de produktie daarvan en antikankermiddelen, die deze lymfocyten bevatten. |
| FR8211489A FR2513882B1 (fr) | 1981-10-01 | 1982-06-30 | Lymphocytes luttant contre les cellules cancereuses, procede pour leur production et agents anticancereux contenant ces lymphocytes ou un antigene glyco-apparente |
| IL66270A IL66270A (en) | 1981-10-01 | 1982-07-08 | Cancer cell-derived glyco-related antigen,its production and anticancer agent containing it |
| DE19823249568 DE3249568A1 (de) | 1981-10-01 | 1982-09-30 | Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs |
| DE19823236298 DE3236298A1 (de) | 1981-10-01 | 1982-09-30 | Krebszellen bekaempfende lymphocyten, verfahren zu deren herstellung und anti-krebsmittel, welche die lymphocyten enthalten |
| GB08228160A GB2106935B (en) | 1981-10-01 | 1982-10-01 | Cancer cell-combatting lymphocytes process for the production thereof and anticancer agents containing said lymphocytes |
| AT0363782A AT382080B (de) | 1981-10-01 | 1982-10-01 | Verfahren zur herstellung von glykoverwandtem antigen |
| CA000412670A CA1195269A (en) | 1981-10-01 | 1982-10-01 | Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes |
| KR8204464A KR880001758B1 (ko) | 1981-10-01 | 1982-10-04 | 암세포에 대항하는 임파구의 제조방법 |
| ES523253A ES523253A0 (es) | 1981-10-01 | 1983-06-14 | "metodo de preparar antigenos glicorrelacionados". |
| IL75524A IL75524A0 (en) | 1981-10-01 | 1985-06-14 | Cancer cell-combating lymphocytes,their production and anticancer agents containing them |
| NO85853541A NO161128C (no) | 1981-10-01 | 1985-09-11 | Fremgangsmaate for fremstilling av kreftcelle-cytotokiske lymfocytter. |
| AT0354585A AT390002B (de) | 1981-10-01 | 1985-12-09 | Verfahren zur herstellung von krebszellen bekaempfenden lymphocyten |
| PH33696A PH23401A (en) | 1981-10-01 | 1986-04-23 | Cancer cell combatting lymphocytes,process for the production thereof and anti-cancer agents,containing said lymphocytes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15641481A JPS5857321A (ja) | 1981-10-01 | 1981-10-01 | 抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5857321A true JPS5857321A (ja) | 1983-04-05 |
| JPH0325408B2 JPH0325408B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-04-05 |
Family
ID=15627222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15641481A Granted JPS5857321A (ja) | 1981-10-01 | 1981-10-01 | 抗癌剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5857321A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5967224A (ja) * | 1982-10-08 | 1984-04-16 | Nippon Koutai Kenkyusho:Kk | 糖鎖関連抗原およびその製造法ならびにこれを有効成分とする抗癌剤 |
| JPS62128903U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1986-02-08 | 1987-08-15 | ||
| JPH05201212A (ja) * | 1991-08-09 | 1993-08-10 | Sumitomo Rubber Ind Ltd | 空気入りタイヤ |
| US5660655A (en) * | 1991-08-09 | 1997-08-26 | Sumitomo Rubber Industries, Ltd. | Tire and rim combination with exhaust ribs in tire bead |
| JP2023503713A (ja) * | 2020-01-19 | 2023-01-31 | ベイジン グリエクソ ジーン テクノロジー カンパニー リミテッド | 臨床サンプルからグリコシル化エクソソームを分離することに用いられるレクチン－磁性担体カップリング複合体 |
| JP2023503711A (ja) * | 2020-01-19 | 2023-01-31 | ベイジン グリエクソ ジーン テクノロジー カンパニー リミテッド | 臨床サンプルからグリコシル化エクソソームを分離することに用いられるレクチン－高分子担体カップリング複合体 |
-
1981
- 1981-10-01 JP JP15641481A patent/JPS5857321A/ja active Granted
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5967224A (ja) * | 1982-10-08 | 1984-04-16 | Nippon Koutai Kenkyusho:Kk | 糖鎖関連抗原およびその製造法ならびにこれを有効成分とする抗癌剤 |
| JPS62128903U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1986-02-08 | 1987-08-15 | ||
| JPH05201212A (ja) * | 1991-08-09 | 1993-08-10 | Sumitomo Rubber Ind Ltd | 空気入りタイヤ |
| US5318089A (en) * | 1991-08-09 | 1994-06-07 | Sumitomo Rubber Industries, Ltd. | Pneumatic tire |
| US5573612A (en) * | 1991-08-09 | 1996-11-12 | Sumitomo Rubber Industries, Ltd. | Tire and rim combination with exhaust means in tire bead |
| US5660655A (en) * | 1991-08-09 | 1997-08-26 | Sumitomo Rubber Industries, Ltd. | Tire and rim combination with exhaust ribs in tire bead |
| JP2023503713A (ja) * | 2020-01-19 | 2023-01-31 | ベイジン グリエクソ ジーン テクノロジー カンパニー リミテッド | 臨床サンプルからグリコシル化エクソソームを分離することに用いられるレクチン－磁性担体カップリング複合体 |
| JP2023503711A (ja) * | 2020-01-19 | 2023-01-31 | ベイジン グリエクソ ジーン テクノロジー カンパニー リミテッド | 臨床サンプルからグリコシル化エクソソームを分離することに用いられるレクチン－高分子担体カップリング複合体 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0325408B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100227302B1 (ko) | 제약 담체 | |
| NZ230747A (en) | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina | |
| DE69112634T2 (de) | Immunogene komplexe, insbesondere iscoms. | |
| JPH0751514B2 (ja) | 免疫原性複合体の製造法 | |
| EP4442272A1 (en) | Vaccine adjuvant, and preparation method therefor and use thereof | |
| NO163668B (no) | Fremgangsmaate for fremstilling av immunogent kompleks. | |
| JPS58216121A (ja) | 精製無毒化エンドトキシン及びその製造方法 | |
| JP2001513575A (ja) | アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物 | |
| KR100354944B1 (ko) | 제약조성물 | |
| JP2002508329A (ja) | 北アメリカ薬用人参分留物の形成方法、それらを含む生成物および免疫賦活剤としての使用方法 | |
| Sharif et al. | The effect of growth stage and isolation method on properties of ClearColi™ outer membrane vesicles (OMVs) | |
| WO2001079302A1 (fr) | Combinaison d'acide folique et de polysaccharide, son procede de preparation et composition pharmaceutique contenant cette combinaison agissant comme principe actif | |
| JPH06500795A (ja) | 選択的トロピズムを有する粒状物ベクター、その製造法及びその製薬学的組成物 | |
| AU583402B2 (en) | Method for the production of a macromolecular carrier loaded with a biologically active substance | |
| JPH0143760B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS5857321A (ja) | 抗癌剤 | |
| CN106729701B (zh) | 阿魏菇多糖作为制备树突状细胞疫苗佐剂的应用 | |
| JP2010530843A (ja) | 抗腫瘍ワクチン、抗腫瘍ワクチンの調製方法及び抗腫瘍免疫療法の実行方法 | |
| Baechtel et al. | Interaction of antigens with dimethyldioctadecylammonium bromide, a chemically defined biological response modifier | |
| US5231081A (en) | Use of hemocyanins and arylphorins to influence the immune system and for the treatment of tumors | |
| JPS6338971B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CN106573047B (zh) | 佐剂 | |
| Shvets et al. | From liposomes of the 1970s to 21st century nanobiotechnology | |
| JPS63164895A (ja) | 培養細胞由来のレクチン様蛋白質及びその製法並びに該物質を主成分とする抗腫瘍剤 | |
| RU2765270C1 (ru) | Композиция растворимых мономерных и олигомерных фрагментов пептидогликана клеточной стенки грамотрицательных бактерий, способы ее получения и применения |